SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...
Morningstar9d
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
risk reduction with use of semaglutide 2.4 mg in a real-world environment1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...
EurekAlert!16h
Coding differences in Medicare Advantage plans led to $33 billion in excess revenue to insurers
An analysis of differential coding patterns between Medicare Advantage (MA) and Traditional Medicare (TM) plans estimated how much coding differs between insurers and how much extra revenue insurers ...
Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Semaglutide: A Cardiovascular Game-Changer
Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...